Welcome to LookChem.com Sign In|Join Free
  • or
Ethyl 3-bromo-4-oxocyclohexanecarboxylate is an organic compound that serves as a crucial reagent in the synthesis of various pharmaceutical compounds. It is characterized by its unique molecular structure, which includes a bromo substituent and a cyclohexane ring with an ester and a carboxylate group. ethyl 3-bromo-4-oxocyclohexanecarboxylate plays a significant role in the development of medications for specific therapeutic applications.

39086-05-0

Post Buying Request

39086-05-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

39086-05-0 Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 3-bromo-4-oxocyclohexanecarboxylate is used as a key reagent for the process development of Pramipexole, a medication used in the therapy of Parkinson's disease. Its unique chemical properties enable the synthesis of Pramipexole, which is a dopamine agonist that helps alleviate the symptoms of Parkinson's disease by mimicking the effects of dopamine in the brain. The use of ethyl 3-bromo-4-oxocyclohexanecarboxylate in the pharmaceutical industry is essential for the development of effective treatments for patients suffering from this neurodegenerative disorder.

Check Digit Verification of cas no

The CAS Registry Mumber 39086-05-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,9,0,8 and 6 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 39086-05:
(7*3)+(6*9)+(5*0)+(4*8)+(3*6)+(2*0)+(1*5)=130
130 % 10 = 0
So 39086-05-0 is a valid CAS Registry Number.

39086-05-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 3-bromo-4-oxocyclohexane-1-carboxylate

1.2 Other means of identification

Product number -
Other names 3-bromo-4-ketocyclohexanecarboxylic acid ethyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:39086-05-0 SDS

39086-05-0Relevant academic research and scientific papers

PROTEIN KINASE C AGONISTS

-

Paragraph 0433, (2020/09/12)

The present disclosure relates generally to certain diacylglycerol lactone compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions dis

BICYCLIC COMPOUND

-

Paragraph 1114, (2017/12/28)

Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.

ISOINDOLINE INHIBITORS OF ROR-GAMMA

-

Paragraph 0311, (2016/06/01)

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS

-

Page/Page column 94; 95, (2015/07/16)

The present invention provides fused thiophene and thiazole derivatives of formula (I), which may be therapeutically useful, more particularly as RORγ modulators; in which R1, R2, R3, R4, R5, R6, R7, X1, X2, L, m, n and ring A have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in disease(s) or disorder(s) where there is an advantage in modulating RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the fused thiophene and thiazole derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

ANTI-INFECTIVE COMPOUNDS

-

Page/Page column 63-64, (2016/06/28)

The present invention relates to small molecule compounds having the general formula (I): wherein A is a moiety selected from the group consisting of formulae (A) to (K) and their use in the treatment of bacterial infections, in particular Tuberculosis.

PYRIDAZINONES AS GPR119 AGONISTS

-

Page/Page column 170, (2011/11/30)

The present invention relates to pyridazinone derivatives of general formula (I), wherein the groups A, G and R1 are as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which

FUSED IMIDAZO [3, 2 - D] PYRAZINES AS PI3 KINASE INHIBITORS

-

Page/Page column 88; 89, (2011/04/24)

There is provided compounds of formula (I), wherein A1, A2, A3, A4, n, the dotted lines, B1, B1a, B2, B2a, B3, B3a, B4, B4a, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

BENZAMIDE COMPOUNDS AS GLUCOKINASE ACTIVATORS AND THEIR PHARMACEUTICAL APPLICATION

-

Page/Page column 48, (2011/09/14)

Benzamide compounds of formula (I), their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof useful as Glucokinase activators or modulators are disclosed. The disclosure further relates to

CYCLOALKYLFUSED INDOLE, BENZOTHIOPHENE, BENZOFURAN AND INDENE DERIVATIVES

-

Page/Page column 45, (2008/06/13)

The present invention provides cycloalkylfused indole, benzothiophene, benzofuran, and indene derivatives, and methods for using them to, for example, treat, prevent and/or ameliorate central nervous system diseases by antagonizing 5-HT1A receptors and mo

GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS

-

Page 47, (2010/02/08)

The invention relates to guanidine derivatives of formula (I) where: A = a chain of 3-c6 carbon atoms, one of which can be replaced by -N(R')- or -O- and R' = H or a substituent, where the ring skeleton only contains both double bonds of the thiazole component, the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I),, comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which are partly known and partly novel and exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence. The above can be produced using generally used methods and processed to give medicaments.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 39086-05-0